LBH589, a hydroxamate analog, is a broad-spectrum HDAC inhibitor. It has been shown to increase acetylation of core histones (H3 and H4) and nonhistone proteins (alpha-tublin, HSP90), leading to the modulation of gene expression (p21, FOXO3A, GADD45A, aromatase, etc) and protein activity involved in cell growth and survival pathways1-4. LBH589 induces apoptosis in MOLT-4 and Reh cells with IC50 between 5 to 20nM1. In lung cancer and mesothelioma animal models, LBH589 markedly decreased tumor growth by 62% when compared with the vehicle control5. The anti-tumor activity of LBH589 has also been demonstrated in many other cancer cell lines, including multiple myeloma, NSCLC and castrate-resistant prostate cancer cell lines. LBH589 is under clinical trials to evaluate its effects in conjunction with chemotherapy and/or targeted therapy in multiple cancer types.